Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Indivior to launch...

    Indivior to launch Sublocade; maintains revenue forecast

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2018-12-21T09:00:57+05:30  |  Updated On 21 Dec 2018 9:00 AM IST
    Indivior to launch Sublocade; maintains revenue forecast


    Indivior also said revenue from its new opioid addiction treatment, Sublocade, would exceed the top end of its previous 2018 forecast range of $8 million to $10 million by about $2 million.


    New Delhi: British drugmaker Indivior Plc recently said it would launch a cheaper version of its blockbuster opioid addiction treatment drug, while maintaining its full-year profit and revenue forecast, sending its shares up more than 20 per cent.


    The company is trying to hold off rivals Dr Reddy's Laboratories and Teva Pharmaceuticals from bringing their copycat versions of Suboxone, which accounts for about 80 per cent of Indivior's revenue.



    Indivior also said revenue from its new opioid addiction treatment, Sublocade, would exceed the top end of its previous 2018 forecast range of $8 million to $10 million by about $2 million.

    The company had cut its revenue estimate for Sublocade in September as it faced distribution challenges.

    Indivior, which was spun off from consumer products group Reckitt Benckiser in 2014, said it expects to meet its full-year forecasts for net revenue of $990 million to $1.02 billion and net income of $230 million to $255 million.

    The company also said it would take steps to cut administrative and research costs to boost profit.

    Indivior said it would move ahead with the launch of Perseris, its injectable drug for treating schizophrenia in adults, in the United States.

    Also Read: Indivior settles addiction treatment case with Mylan for undisclosed terms



    Indivioropioidopioid addiction drugPerserisReckitt BenckiserschizophreniaSuboxoneTeva PharmaceuticalsUnited States
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok